Archive | Of Interest

Analyzing tumor microenvironment at single cell level sheds light on metastatic melanoma outcomes

There are several new treatment options available for patients with advanced melanoma. While these therapies have greatly improved the prognosis for patients, each person can respond to the treatments differently.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Improved Responses Sustained With Pembrolizumab in Treatment-Naïve Melanoma, But Not in Rechallenged Patients

Patients with stage III melanoma who progressed following placebo-based treatment in the first part of the phase 3 EORTC 1325/KEYNOTE-054 trial (NCT02362594) and crossed over to receive pembrolizumab…

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Adjuvant pembrolizumab extends RFS in high-risk melanoma

Pembrolizumab extended RFS compared with high-dose interferon or ipilimumab as adjuvant therapy for patients with high-risk melanoma, according to randomized phase 3 study results presented during the virtual ASCO Annual Meeting.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Nivolumab Alone, With Ipilimumab Maintains Improved Outcomes in Advanced Melanoma in Long-Term Follow-Up

Nivolumab (Opdivo) monotherapy or in combination with ipilimumab (Yervoy) continued to show durable improvements in overall survival (OS) compared with ipilimumab alone in patients with previously untreated advanced melanoma

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest